Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
ESMO 2022: Best approaches to bladder preservation
Prof Morgan Rouprêt and Prof Nick James
ESMO 2022: Best approaches to bladder preservation ( Prof Morgan Rouprêt and Prof Nick James )
27 Sep 2022
Xevinapant plus standard of care chemoradiotherapy improved 5 year OS for unrese...
Prof Jean Bourhis - University Hospital of Lausanne, Lausanne, Switzerland
Xevinapant plus standard of care chemoradiotherapy improved 5 year OS for unresected LA SCCHN ( Prof Jean Bourhis - University Hospital of Lausanne, Lausanne, Switzerland )
27 Sep 2022
Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced br...
Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA
Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )
21 Sep 2022
ESMO 2022: Breast and ovarian trial analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2022: Breast and ovarian trial analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
14 Sep 2022
ERMES study suggests a strategy of de-escalation with only cetuximab in first li...
Dr Armando Orlandi - Agostino Gemelli University Polyclinic, Rome, Italy
ERMES study suggests a strategy of de-escalation with only cetuximab in first line therapy for RAS and BRAF wild type mCRC ( Dr Armando Orlandi - Agostino Gemelli University Polyclinic, Rome, Italy )
14 Sep 2022
Neoadjuvant immunotherapy improves outlook in high-risk melanoma
Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA
Neoadjuvant immunotherapy improves outlook in high-risk melanoma ( Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA )
14 Sep 2022
Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible loca...
Prof Jonathan E Rosenberg - Memorial Sloan Kettering Cancer Center, New York Cit...
Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible locally advanced or metastatic urothelial cancer ( Prof Jonathan E Rosenberg - Memorial Sloan Kettering Cancer Center, New York City, USA )
14 Sep 2022
Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-li...
Dr Marcin Dzienis - Gold Coast University Hospital, Southport, Australia
Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-line recurrent/metastatic HNSCC ( Dr Marcin Dzienis - Gold Coast University Hospital, Southport, Australia )
14 Sep 2022
ESMO 2022: Highlights, commentary and analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2022: Highlights, commentary and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
12 Sep 2022
Updates in prostate cancer from ESMO 2022
Prof Eleni Efstathiou, Prof Gerhardt Attard and Prof Boris Hadaschik
Updates in prostate cancer from ESMO 2022 ( Prof Eleni Efstathiou, Prof Gerhardt Attard and Prof Boris Hadaschik )
12 Sep 2022
ESMO 2022: Renal roundup
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
ESMO 2022: Renal roundup ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
12 Sep 2022
ESMO 2022: Breast cancer highlights
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
ESMO 2022: Breast cancer highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
12 Sep 2022